Barclays Forecasts Strong Price Appreciation for DexCom (NASDAQ:DXCM) Stock

DexCom (NASDAQ:DXCM) had its target price boosted by Barclays from $115.00 to $120.00 in a research note issued to investors on Friday, Benzinga reports. The brokerage presently has an “overweight” rating on the medical device company’s stock. Barclays‘s price target would suggest a potential upside of 41.94% from the company’s current price.

A number of other equities research analysts have also recently weighed in on the company. Royal Bank Of Canada restated an “outperform” rating and issued a $105.00 price target (up from $90.00) on shares of DexCom in a report on Thursday, October 1st. Weiss Ratings raised DexCom from a “hold (c)” rating to a “hold (c+)” rating in a report on Tuesday, October 6th. BTIG Research lifted their price objective on DexCom from $90.00 to $96.00 and gave the stock a “buy” rating in a report on Monday, October 12th. Argus upped their target price on DexCom from $86.00 to $96.00 and gave the company a “buy” rating in a report on Tuesday, August 4th. Finally, Robert W. Baird set a $105.00 target price on DexCom in a report on Friday, July 31st. Two equities research analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, DexCom has a consensus rating of “Buy” and a consensus target price of $92.78.

DexCom Price Performance

Shares of NASDAQ DXCM traded up $4.61 during midday trading on Friday, hitting $84.54. The company had a trading volume of 2,253,831 shares, compared to its average volume of 5,000,788. The firm has a market capitalization of $31.90 billion, a price-to-earnings ratio of 33.12, a price-to-earnings-growth ratio of 1.32 and a beta of 1.48. DexCom has a twelve month low of $54.11 and a twelve month high of $92.59. The business has a 50-day simple moving average of $85.98 and a two-hundred day simple moving average of $74.60. The company has a quick ratio of 1.43, a current ratio of 1.73 and a debt-to-equity ratio of 0.47.

DexCom (NASDAQ:DXCM) last issued its earnings results on Thursday, October 29th. The medical device company reported $0.73 earnings per share for the quarter, topping the consensus estimate of $0.68 by $0.05. DexCom had a net margin of 20.12% and a return on equity of 35.94%. The company had revenue of $1.34 billion for the quarter, compared to analyst estimates of $1.33 billion. During the same period in the prior year, the business posted $0.61 earnings per share. The firm’s revenue for the quarter was up 11.1% compared to the same quarter last year. Equities research analysts anticipate that DexCom will post 2.64 earnings per share for the current year.

Insider Buying and Selling at DexCom

In related news, EVP Michael Brown sold 1,700 shares of DexCom stock in a transaction that occurred on Thursday, October 15th. The stock was sold at an average price of $85.48, for a total transaction of $145,316.00. Following the completion of the transaction, the executive vice president directly owned 98,185 shares in the company, valued at $8,392,853.80. The trade was a 1.70% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Jereme M. Sylvain sold 3,638 shares of the company’s stock in a transaction that occurred on Thursday, September 10th. The shares were sold at an average price of $83.27, for a total value of $302,936.26. Following the completion of the sale, the executive vice president directly owned 146,828 shares in the company, valued at approximately $12,226,367.56. The trade was a 2.42% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 24,822 shares of company stock worth $2,090,833. 0.28% of the stock is currently owned by insiders.

Institutional Trading of DexCom

Several institutional investors and hedge funds have recently made changes to their positions in DXCM. Plato Investment Management Ltd purchased a new stake in shares of DexCom during the second quarter worth about $782,000. Aurora Investment Counsel purchased a new position in shares of DexCom during the second quarter valued at approximately $2,340,000. E Fund Management Co. Ltd. purchased a new position in shares of DexCom during the second quarter valued at approximately $1,273,000. Silvant Capital Management LLC acquired a new stake in DexCom during the second quarter worth approximately $5,359,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in DexCom during the second quarter worth approximately $89,940,000. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting DexCom

Here are the key news stories impacting DexCom this week:

• Positive Sentiment: Strong third-quarter results: DexCom reported adjusted earnings of $0.73 per share, exceeding consensus estimates of approximately $0.66–$0.68, while revenue of $1.34 billion topped expectations by about $10 million. Revenue increased roughly 11% year over year, and operating profit rose sharply, highlighting continued margin improvement. DexCom Third-Quarter Earnings Results
• Positive Sentiment: Higher outlook: Management raised its 2026 sales guidance, reinforcing investor confidence that demand for DexCom’s continuous glucose monitoring products remains resilient. DexCom Raises Sales Guidance
• Positive Sentiment: $1 billion buyback: DexCom authorized an equity repurchase program worth up to $1.0 billion. The plan may support earnings per share and signals that management views the company’s shares as an attractive use of capital. DexCom Announces $1 Billion Buyback
• Positive Sentiment: Product expansion: DexCom plans to launch its G7 15-day continuous glucose monitoring system in Canada in November, expanding the availability of its newest platform. DexCom G7 15-Day Canada Launch
• Negative Sentiment: Insider selling: Executive Vice President Sadie Stern sold 2,565 shares for approximately $202,000 under a pre-arranged Rule 10b5-1 plan. The scheduled nature of the transaction reduces its significance, but continued insider sales may temper sentiment. DexCom Insider Sale

DexCom Company Profile

DexCom, Inc develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes. Its devices use a small wearable sensor to measure glucose levels in real time and transmit readings to compatible smartphones, receivers, smartwatches, and other connected devices, helping users monitor glucose trends and make informed decisions about their health.

The company’s product portfolio includes the Dexcom G7 and Dexcom G6 CGM systems, as well as Dexcom ONE and Dexcom ONE+ products offered in select markets.